Side-by-side · Research reference

SurvodutidevsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED25/54 cited

BPhase 3HUMAN-REVIEWED8/39 cited

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Survodutide

Thymosin α-1

Primary target

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

—

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

Survodutide

Thymosin α-1

Standard dose

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

—

Frequency

Once weekly

2× weekly (Mon/Thu typical)

Route

SubcutaneousYathindra 2026

—

Evidence basis

Phase 2 RCT (obesity) · Phase 3 ongoing

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Phase 2 findings

Significant weight loss and metabolic marker improvementYathindra 2026

—

MASH indication

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

—

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Lower / starter dose

—

0.8 mg per injection

Duration

—

6–12 months for chronic indications

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

03Metabolic / Fat Loss Evidence

Parameter

Survodutide

Thymosin α-1

Primary fat target

Total body weight, visceral adipose tissue

—

Weight loss mechanism

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

—

Phase 2 efficacy

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

—

Metabolic markers

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

—

MRI-PDFF reduction

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

—

Network meta-analysis

Favorable efficacy profile vs other glucagon receptor agonists

—

Hepatic requirement

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

—

Energy expenditure

Increased energy expenditure contributes to weight lossZimmermann 2026

—

Comparative efficacy

Network meta-analysis shows competitive efficacy in GRA class

—

04Side Effects & Safety

Parameter

Survodutide

Thymosin α-1

GI symptoms

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Rare nausea

Safety profile

Network meta-analysis: comparable safety to other GRAs

—

Serious adverse events

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

—

Injection site reactions

Expected with subcutaneous administration

—

Glucagon-related effects

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

—

Injection site reaction

—

Erythema, mild discomfort

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Survodutide

Thymosin α-1

1. Reconstitution

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

2× weekly, e.g. Monday + Thursday.

4. Storage

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

27–31G, 4–8 mm insulin syringe.